Bioxytran annual stock-based compensation
2019
2020
2021
2022
2023
2024
2025
Bioxytran Stock-Based Compensation Growth & History (BIXT)
Bioxytran's stock-based compensation was $197,376 for fiscal 2025.
View full Bioxytran company overviewBioxytran annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $197,376 | −$436,649 | −68.87% |
| 2024 | 2024-12-31 | $634,025 | $545,925 | +619.67% |
| 2023 | 2023-12-31 | $88,100 | −$51,882 | −37.06% |
| 2022 | 2022-12-31 | $139,982 | −$442,880 | −75.98% |
| 2021 | 2021-12-31 | $582,862 | $334,995 | +135.15% |
| 2020 | 2020-12-31 | $247,867 | −$873,827 | −77.90% |
| 2019 | 2019-12-31 | $1.1M | — | — |
Bioxytran quarterly stock-based compensation
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $7,815 | −$34,248 | −81.42% |
| Q1 2026 | 2026-03-31 | $1.3M | $1.3M | +4678.19% |
| Q4 2025 | 2025-12-31 | $84,574 | −$361,934 | −81.06% |
| Q3 2025 | 2025-09-30 | $43,741 | $35,325 | +419.74% |
| Q2 2025 | 2025-06-30 | $42,063 | $31,372 | +293.44% |
| Q1 2025 | 2025-03-31 | $26,998 | −$141,412 | −83.97% |
| Q4 2024 | 2024-12-31 | $446,508 | $440,936 | +7913.42% |
| Q3 2024 | 2024-09-30 | $8,416 | −$72,902 | −89.65% |
| Q2 2024 | 2024-06-30 | $10,691 | $10,331 | +2869.72% |
| Q1 2024 | 2024-03-31 | $168,410 | $167,560 | +19712.94% |
| Q4 2023 | 2023-12-31 | $5,572 | — | — |
| Q3 2023 | 2023-09-30 | $81,318 | $7,811 | +10.63% |
| Q2 2023 | 2023-06-30 | $360 | −$46,363 | −99.23% |
| Q1 2023 | 2023-03-31 | $850 | −$21,550 | −96.21% |
| Q3 2022 | 2022-09-30 | $73,507 | $72,663 | +8609.36% |
| Q2 2022 | 2022-06-30 | $46,723 | −$4,327 | −8.48% |
| Q1 2022 | 2022-03-31 | $22,400 | −$752,158 | −97.11% |
| Q3 2021 | 2021-09-30 | $844 | −$8,364 | −90.83% |
| Q2 2021 | 2021-06-30 | $51,050 | $41,559 | +437.88% |
| Q1 2021 | 2021-03-31 | $774,558 | $619,057 | +398.10% |
| Q4 2020 | 2020-12-31 | $73,667 | — | — |
| Q3 2020 | 2020-09-30 | $9,208 | — | — |
| Q2 2020 | 2020-06-30 | $9,491 | — | — |
| Q1 2020 | 2020-03-31 | $155,501 | — | — |
Bioxytran stock-based compensation trends
Over the last five fiscal years, Bioxytran's stock-based compensation decreased from $247,867 to $197,376, a change of −$50,491. The latest reported quarter, Q2 2026, shows $7,815.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Bioxytran source filings ↗